CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 6 enrolled
Drug / intervention
Recombinant Human Prolactindrug
Likely dose
Not stated in record
Key inclusion· 8
  • ✓Healthy women aged 18-45 years
  • ✓Prolactin deficiency from congenital deficiency, surgery, radiation, or Sheehan's syndrome during current or previous pregnancies
  • ✓Postpartum at time of study participation
  • ✓Milk fails to come in by 2-4 days after delivery
Key exclusion· 7
  • ✕Current use of medications known to increase or decrease prolactin
  • ✕Anatomical breast abnormalities
  • ✕Previous mammoplasty
  • ✕Breast augmentation

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00181623
NCT00181623Phase 2Completed
CompareCT.gov

Recombinant Human Prolactin for Lactation Induction in Prolactin Deficient Mothers

Massachusetts General Hospital·interventional·Posted Sep 16, 2005·Updated Dec 11, 2017

In Brief

A Phase 2 clinical trial evaluating Recombinant Human Prolactin for Lactation. Completed, enrolled 6 participants across 1 site.

Detailed Summary

The purpose of the study is to assess the safety and determine the effects of the hormone prolactin on lactation (breast milk production).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLactation
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 16, 2005
Enrollment StartJan 1, 2005
Primary CompletionMay 1, 2011
TodayJul 2, 2026
Enrollment to primary: 6.3 yearsPosted 20.8 years ago

Interventions

Recombinant Human Prolactindrug